Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123178) titled 'Tislelizumab in Neoadjuvant Therapy for pMMR/MSS Rectal Cancer: Long-course vs Short-course Radiotherapy-A Randomized Trial' on April 22.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Condition:
rectal cancer
Intervention:
Long-course Chemoradiotherapy Group:Long-course radiotherapy + concurrent tislelizumab + CAPOX chemotherapy for 2 cycles ? tislelizumab + CAPOX chemotherapy for 4 cycles ? surgery or watch-and-wait within 4-8 weeks after the last dose of capecitabine
Recruitment Status: Not Recruiting
Ph...